Ge Long Hui·2026-01-23 07:41Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval - The Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunct therapy for epilepsy [1] - The product's research and development were completed by Changzhou Pharmaceutical Factory in October 2019, and it received approval from the U.S. Food and Drug Administration in July 2021 [1] Group 2: Market Expansion - The Pregabalin capsules also received approval from the Thai Food and Drug Administration for market entry by June 2025 [1] - The company has invested approximately RMB 2.19 million in research and development for the product's launch in Southeast Asian markets, including Thailand, Singapore, Malaysia, and the Philippines [1]